Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity. Nordenskjold AE, Rios-Romero M, Dar H, Fornander T, et al. Int J Cancer 2026 Mar 5. doi: 10.1002/ijc.70409.

Read + Share

Amedeo Smart

Independent Medical Education

Nordenskjold AE, Rios-Romero M, Dar H, Fornander T, et al. Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity. Int J Cancer 2026 Mar 5. doi: 10.1002/ijc.70409.
PMID: 41787605